About SciClone Pharmaceuticals
SciClone Pharmaceuticals is a company based in Shanghai (China) founded in 1989 was acquired by BOC Investment in June 2017. SciClone Pharmaceuticals has completed 1 acquisition, including NovaMed Pharmaceuticals.
- Headquarter Shanghai, China
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sciclone Pharmaceuticals Inc
-
Annual Revenue
$160.1 M (USD)2as on Dec 31, 2016
-
Net Profit
$30.73 M (USD)4as on Dec 31, 2016
-
EBITDA
$33.24 M (USD)11as on Dec 31, 2016
-
Latest Funding Round
Not available
-
Investors
Ascendent Capital Partners
& 3 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
BOC Investment
(Jun 07, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of SciClone Pharmaceuticals
Unlock access to complete
Funding Insights of SciClone Pharmaceuticals
Detailed funding history for SciClone Pharmaceuticals
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in SciClone Pharmaceuticals
SciClone Pharmaceuticals has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Ascendent Capital Partners, GL Capital and BOC Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Private equity investments in China are managed by BOC Investment.
|
Locked | Locked | Locked | |
|
Private equity and private debt firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for SciClone Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SciClone Pharmaceuticals
SciClone Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include NovaMed Pharmaceuticals.
Investment portfolio details for SciClone Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for oncology, cardiovascular, and CNS disorders are developed.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for SciClone Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - SciClone Pharmaceuticals
Detailed financials for SciClone Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sciclone Pharmaceuticals Comparisons
Peer comparison for SciClone Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SciClone Pharmaceuticals
Detailed competitors of SciClone Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sciclone Pharmaceuticals
Complete news archive for SciClone Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SciClone Pharmaceuticals
SciClone Pharmaceuticals was founded in 1989.
SciClone Pharmaceuticals is headquartered in Shanghai, China.
Annual revenue of SciClone Pharmaceuticals is $160.1M as on Dec 31, 2016.
Sciclone is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. It has 7 marketed products in oncology and 1 product (Zadaxin) for HBV, HCV, immune system enhancement and sepsis. Product pipeline includes rapidfilm (CFDA reviewing CTA) and SGX942 (phase 2) in oncology; angiomax (CFDA review), neucardin (phase 3) and cleviprex (CTA application filed) in cardiovascular segment; and loramyc (In clinical testing) and vibativ (CTA application planning) in anti-infectives category.
SciClone Pharmaceuticals has made 1 acquisition, including NovaMed Pharmaceuticals.
SciClone Pharmaceuticals has 4 investors. Key investors include Ascendent Capital Partners, GL Capital, BOC Investment, and CDH.